Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- University of Colorado, Boulder
- Enrollment
- 29
- Locations
- 1
- Primary Endpoint
- Walking Endurance
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to investigate the capacity of a 6-week treatment with neuromuscular electrical stimulation to improve walking in individuals whose mobility has been compromised by multiple sclerosis.
Detailed Description
Participants will be randomly assigned to one of two study arms. Those in one arm will receive a treatment with narrow stimulus pulses (0.4 ms) and those in the other arm will receive wide stimulus pulses (1 ms). The electrical stimulation will be delivered with a Vectra Genisys System.
Investigators
Roger Enoka
Professor
University of Colorado, Boulder
Eligibility Criteria
Inclusion Criteria
- •Able to read, understand, and speak English to ensure safe participation in the project
- •Difficulties with walking
- •On stable doses of Ampyra, provigil, or other symptomatic-treating medications
- •No systemic steroids within the last 30 days
- •Not currently exercising more than 2x/wk
- •Able to arrange own transportation to and from the laboratories
- •Provide informed consent, including willingness to be randomly assigned to one of the two groups
Exclusion Criteria
- •Documented MS-related relapse in the last 3 months
- •Medical diagnosis or condition that is considered to be an absolute or relative contraindication to participating in exercise training, such as major renal, pulmonary, hepatic, cardiac, gastrointestinal, HIV, cancer (other than treated basal cell cancer), other neurological disorders, or pregnancy
- •Poorly controlled diabetes mellitus or hypertension
- •History of seizure disorders
- •Alcohol dependence or abuse (≥2 drinks/day), or present history (last 6 months) of drug abuse
- •Inability to attend exercise sessions 3 days per week for 6 weeks
Outcomes
Primary Outcomes
Walking Endurance
Time Frame: Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
Distance walked in 6 min
Modified Fatigue Impact Scale
Time Frame: Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).
MFIS scores range from 0 to 84 and higher numbers indicating worse fatigue.
Secondary Outcomes
- Maximal Walking Speed(Change from before to after 18 treatment sessions administered over a 6-week period (3 sessions/week).)